Why GSK took Unilever shares for Indian Horlicks deal

GlaxoSmithKline’s sale of the malted drink came at a high price but mostly in shares.

Why GSK took Unilever shares for Indian Horlicks deal

British pharmaceutical group GlaxoSmithKline secured the high price of 3.1 billion $3.97 billion for the sale of its Indian business, but the proceeds are mostly in shares rather than cash.

GlaxoSmithKline said on Monday that it would sell Horlicks and other consumer healthcare nutrition brands to Unilever as well as merge GSK Consumer Healthcare India with Unilever’s Indian unit, Hindustan Unilever.

The assets fetched a high valuation...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: unilever | india | acquisitions | glaxosmithkline

Print Edition

FinanceAsia Print Edition

EVENTS